English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/61859
logo share SHARE   Add this article to your Mendeley library MendeleyBASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:


New treatments for multiple myeloma

AuthorsMateos, Maria Victoria; Ocio, Enrique M. ; San Miguel, Jesús F.
Issue Date2007
PublisherPublicaciones Permanyer
CitationCancer and Chemotherapy Reviews 2(4): 218-231 (2007)
AbstractMultiple myeloma remains an incurable disease. Consequently, an increasing interest in the investigation of new therapeutic alternatives that could improve the outcome of these patients has been experienced in the last years. These approaches are usually based in a more specific drug design, targeting both the pathogenetic mechanisms of multiple myeloma and the interactions of multiple myeloma plasma cells with the bone marrow microenvironment. In the present review we have examined the current status of the preclinical and clinical development of these compounds. The first section focuses on the results of the main studies that have analyzed the efficacy of the only three drugs that have been approved in the last 20 years for the treatment of multiple myeloma patients: thalidomide, lenalidomide and bortezomib. We have separately analyzed the studies in newly diagnosed patients and in relapsed and/or refractory patients. These results show how the three drugs display a very promising activity both when used as monotherapy and, mainly, in combination with other drugs such as dexamethasone, doxorubicin and melphalan. This has led to an important improvement in the remission rates and median survival of multiple myeloma patients. Similar to what occurred with thalidomide, lenalidomide and bortezomib, many other targeted compounds are currently being explored as antimyeloma agents. The second part of the review is an overview of the studies that have demonstrated activity of these novel agents, both in the field of preclinical development and in a clinical trial setting. These agents have been classified into different groups according to their mechanism of action. In summary, we demonstrate how the recently approved antimyeloma agents have changed the outcome of multiple myeloma patients, and we also gain further insight into the future perspectives of those new targeted compounds, which will soon increase the treatment armamentarium against this disease.
Identifiersissn: 1885-740X
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.